CTRC Core

摘要/摘要 临床和翻译研究核心(CTRC) 临床和转化性研究核心(CTRC)为神经退行性疾病提供基础设施 (NDD)神经变性和转化神经科学中心(CNTN)的临床研究。在……里面 第一阶段，Core招募、表征和保留了一个由190多名深度临床队列组成的临床队列 五个诊断组的研究参与者：轻度认知障碍(MCI)，轻度 阿尔茨海默病(AD)、无认知障碍的帕金森病(PD-NC)、轻度PD 认知障碍(PD-MCI)和认知正常对照(NC)。直接支持此队列中的数据 第一阶段5个项目的研究目标，以及其他几个合作项目。在第二阶段，核心将扩展 这项研究长达十年。与第一阶段一样，反恐委员会将向每个项目负责人提供业务和 监管支持、项目管理和研究指导，将帮助他们朝着目标前进 独立的资金来源。第二阶段对临床核心的一个显著增强包括对 NDD中的神经炎症。CTRC对神经炎症的多模式方法(包括神经成像， 基于血液的生物标志物、遗传学和临床评估)代表了首批全面的 NDD领域的数据库。除了维持临床核心，CTRC将专注于增加 传统上代表性不足的患者群体的参与率。将通过以下方式促进参与 扩大我们的教育和外展计划。本计划在第一阶段实施，是有指导意义的 来自社区咨询委员会(CAB)的意见，并包括一个创新的教育和外联网站 (Healhybrains.org)。最后，CORE还将在内华达州南部的加州大学建立第一个生物库 内华达州-拉斯维加斯(UNLV)在杰斐逊·金尼博士的指导下。这一新资源将存储、分析 并在非临床和临床生物检疫的评估方面提供专业知识。除了支持 目前提议的项目，更多的Cobre和非Cobre合作者将访问此 宝贵的资源。反恐委员会在其中嵌入了形成性和总结性评估，以确保 在实现其特定目标方面取得成功。

SUMMARY/ABSTRACT Clinical and Translational Research Core (CTRC) The Clinical and Translational Research Core (CTRC) provides the infrastructure for neurodegenerative disease (NDD) clinical research within the Center for Neurodegenerative and Translational Neuroscience (CNTN). In Phase 1, the Core recruited, characterized, and retained a clinical cohort consisting of more than 190 “deeply phenoyped” research participants across five diagnostic groups: mild cognitive impairment (MCI), mild Alzheimer’s disease (AD), Parkinson’s disease (PD) with no cognitive impairment (PD-NC), PD with mild cognitive impairment (PD-MCI), and cognitively normal controls (CNC). Data from this cohort directly supported the research goals of 5 projects in Phase 1, as well several other collaborations. In Phase 2, the core will extend the study up to ten years. As in Phase 1, the CTRC will provide each project leader with operational and regulatory support, project management, and research instruction that will help advance them toward the goal of independent funding. A notable enhancement of the Clinical Core in Phase 2 includes a focus on the role of neuroinflammation in NDD. The CTRC’s multimodal approach to neuroinflammation (including neuroimaging, blood-based biomarkers, genetics, and clinical assessments) represents one of the first comprehensive databases in the field of NDD. In addition to sustaining the clinical core, the CTRC will focus on increasing participation rates of traditionally underrepresented patient populations. Participation will be facilitated through expansion of our education and outreach program. This program, which was implemented in Phase 1, is guided by input from a Community Advisory Board (CAB) and includes an innovative education and outreach website (Healthybrains.org). Finally, the core will also establish the first biobank in Southern Nevada at the University of Nevada-Las Vegas (UNLV) under the direction of Dr. Jefferson Kinney. This new resource will store, analyze, and provide expertise in the evaluation of non-clinical and clinical biospecimens. In addition to supporting the currently proposed projects, a number of additional COBRE and non-COBRE collaborators will access this valuable resource. The CTRC has formative and summative assessments imbedded within in that will insure success in achieving its specific aims.